<DOC>
	<DOCNO>NCT00125541</DOCNO>
	<brief_summary>A multicentre study investigate pharmacokinetics , clinical efficacy safety nanofiltered Cetor® ( call C1-esteraseremmer-N development phase ) treatment hereditary angioedema ( HAE ) perform . This study ( KB2003.01 ) consist three part : Part A - pharmacokinetics ( phase II ) ; Part B - treatment attack angioedema ( phase III ) ; Part C - prophylactic use C1 inhibitor ( phase III ) . Parts B + C provide data efficacy C1-esteraseremmer-N . The change within manufacture process C1-esteraseremmer-N , compare Cetor® nanofiltration omission hepatitis B immunoglobulin , likely affect tolerability . The nanofiltration provide safety regard virus . In part C study , number HAE patient treat prophylactically open-label C1-esteraseremmer-N period 16 week . The number attack occur compare historical data . If possible , also patient treat prophylactically C1 inhibitor acquire angioedema include .</brief_summary>
	<brief_title>C1-Esteraseremmer-N Treatment Hereditary ( Acquired ) Angioedema</brief_title>
	<detailed_description>A multicentre study investigate pharmacokinetics , clinical efficacy safety nanofiltered Cetor® ( call C1-esteraseremmer-N development phase ) treatment hereditary angioedema ( HAE ) perform . This study ( KB2003.01 ) consist three part : Part A - pharmacokinetics ( phase II ) ; Part B - treatment attack angioedema ( phase III ) ; Part C - prophylactic use C1 inhibitor ( phase III ) . Parts B + C provide data efficacy C1-esteraseremmer-N . The change within manufacture process C1-esteraseremmer-N , compare Cetor® nanofiltration omission hepatitis B immunoglobulin , likely affect tolerability . The nanofiltration provide safety regard virus . In part C study , number HAE patient treat prophylactically open-label C1-esteraseremmer-N period 16 week . The number attack occur compare historical data . If possible , also patient treat prophylactically C1 inhibitor acquire angioedema include .</detailed_description>
	<mesh_term>Angioedema</mesh_term>
	<mesh_term>Complement C1 Inactivator Proteins</mesh_term>
	<criteria>Inclusion criterion hereditary angioedema patient : Established diagnosis hereditary angioedema type I II : markedly decrease C1 inhibitor activity ; decrease ( type I ) , normal elevate ( type II ) level C1 inhibitor antigen ; decrease level C4 . Patients already use C1 inhibitor concentrate prophylaxis angioedema attack . Age ≥ 16 year Signed informed consent patient patient 's legal representative 18 year old Inclusion criterion acquire angioedema patient : Established diagnosis acquire angioedema : recurrent attack angioedema without urticaria ; family history ; decrease functional C1 inhibitor ; decrease level C4 . Autoantibodies C1 inhibitor decrease C1q onset third decade life . Age ≥ 16 year Patient already use C1 inhibitor concentrate prophylaxis angioedema attack Signed informed consent patient patient 's legal representative 18 year old Exclusion criterion hereditary angioedema patient : Use angioedema prophylactic medication study , C1esteraseremmerN . Change oral contraceptive start last two month start trial end study period . Presence clinically relevant C1 inhibitor auto antibody Participation another pharmaceutical clinical study , interfere study , last 3 month prior study , part A protocol . Usage heparin start last two day prior study end study period . Bcell malignancy Pregnancy lactation History allergic reaction C1 inhibitor concentrate blood product Exclusion criterion acquire angioedema patient : Participation another pharmaceutical clinical study , interfere study , last 3 month prior study Usage heparin within last two day prior study Pregnancy lactation History allergic reaction C1 inhibitor concentrate blood product</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>MeSH : angioneurotic edema , complement 1 inactivators</keyword>
	<keyword>Hereditary Angioedema Type I II , Acquired Angioedema</keyword>
</DOC>